Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment.

von Matt, Stefanie; Bacher, Ulrike; Banz, Yara; Mansouri Taleghani, Behrouz; Novak, Urban; Pabst, Thomas (2023). Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment. Mediterranean journal of hematology and infectious diseases, 15(1), e2023025. Università Cattolica del Sacro Cuore 10.4084/MJHID.2023.025

[img]
Preview
Text
Bacher_PDF.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (734kB) | Preview

INTRODUCTION

Autologous stem cell transplantation (ASCT) following high-dose chemotherapy is applied as salvage therapy in patients with relapsed disease or as first-line consolidation in high-risk DLBCL with chemo-sensitive disease. However, the prognosis of relapsing DLBCL post-ASCT remained poor until the availability of CAR-T cell treatment. To appreciate this development, understanding the outcome of these patients in the pre-CAR-T era is essential.

METHODS

We retrospectively analyzed 125 consecutive DLBCL patients who underwent HDCT/ASCT.

RESULTS

After a median follow-up of 26 months, OS and PFS were 65% and 55%. Fifty-three patients (42%) had a relapse (32 patients, 60%) or refractory disease (21 patients, 40%) after a median of 3 months post-ASCT. 81% of relapses occurred within the first year post-ASCT with an OS of 19% versus 40% at the last follow-up in patients with later relapses (p=0.0022). Patients with r/r disease after ASCT had inferior OS compared to patients in ongoing remission (23% versus 96%; p<0.0001). Patients relapsing post-ASCT without salvage therapy (n=22) had worse OS than patients with 1-4 subsequent treatment lines (n=31) (OS 0% versus 39%; median OS 3 versus 25 months; p<0.0001). Forty-one (77%) of patients relapsing after ASCT died, 35 of which due to progression.

CONCLUSIONS

Additional therapies can extend OS but mostly cannot prevent death in DLBCL relapsing/refractory post-ASCT. This study may serve as a reference to emerging results after CAR-T treatment in this population.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Bacher, Vera Ulrike, Banz Wälti, Yara Sarah, Mansouri Taleghani, Behrouz, Novak, Urban, Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

2035-3006

Publisher:

Università Cattolica del Sacro Cuore

Language:

English

Submitter:

Pubmed Import

Date Deposited:

15 May 2023 15:25

Last Modified:

21 May 2023 02:26

Publisher DOI:

10.4084/MJHID.2023.025

PubMed ID:

37180203

Uncontrolled Keywords:

Autologous stem cell transplantation (ASCT) Chimeric antigen receptor T-cell (CAR-T) Diffuse large B-cell lymphoma (DLBCL)

BORIS DOI:

10.48350/182552

URI:

https://boris.unibe.ch/id/eprint/182552

Actions (login required)

Edit item Edit item
Provide Feedback